- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02667535
PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure
Pharmacokinetics, Pharmacodynamics and Safety Comparative Trial of Isosorbide Mononitrate Gel in Participants With Anal Fissure and Healthy Volunteers.
Study Overview
Detailed Description
This is a Phase I, open-label, parallel trial to evaluate Pharmacokinetics, Pharmacodynamics and Safety of Isosorbide Mononitrate gel for usage in participants with anal fissure and healthy volunteers.
Investigational product will be randomly assigned as follows:
- healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days;
- participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects aged ≥ 18 years-old;
- Body mass index (BMI) ≥ 19 Kg/m2 and ≤ 35 Kg/m2;
- For healthy volunteers: good health conditions or without significant diseases, according to best medical judgement, according to protocol requirements and study evaluations: medical history, blood pressure and heart rate measurements, physical examination, electrocardiogram (ECG) and screening laboratory tests;
- For participants with the condition under study: anal fissure;
- Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature.
Exclusion Criteria:
- Known hypersensitivity to the investigational products (naproxen or rebamipide) or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug;
- Chronic therapy with any drugs, except oral contraceptives and medication authorized by principal investigator (each case to be individually evaluated);
- History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, or any other co-morbidity that requires priority immediate treatment ot that, at principal investigator discretion, might interfere with study participation or expose study participant to risks other than predicted;
- Deviations on screening laboratory results that are considered as clinically relevant by the principal investigator;
- Smoking;
- History of drugs and alcohol addiction or excessive alcohol consumption (> 35 g/ day);
- Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except oral contraceptives or cases which, based on drug's or metabolite's half-life, complete elimination can be assumed;
- Treatment, within 6 months before the trial, with any drugs known to have a well established toxic potential to major organs;
- Participation in any other experimental research or administration of any experimental drug within six months before this trial;
- Donation or loss of 450 mL of blood (or more) within 3 months before the trial, or 4 donations within 12 months before the trial;
- Any condition, according to investigator's best judgement, that prevents the subject to participate in the trial;
- Pregnancy, labor or miscarriage with 12 weeks before admission predicted date.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Isosorbide Mononitrate 2.0% healthy
Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
|
Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days. Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days. |
Experimental: Isosorbide Mononitrate 0.5% anal fissure
Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
|
Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days. Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days. |
Experimental: Isosorbide Mononitrate 1.0% anal fissure
Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
|
Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days. Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days. |
Experimental: Isosorbide Mononitrate 2.0% anal fissure
Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
|
Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days. Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics, area under the curve time zero - last (AUC t0-last)
Time Frame: 7 days
|
7 days
|
Pharmacokinetics, area under the curve time zero - infinite (AUC t0-inf)
Time Frame: 7 days
|
7 days
|
Pharmacokinetics, constant of elimination (Ke)
Time Frame: 7 days
|
7 days
|
Pharmacokinetics, half-life (t1/2)
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety, by number of adverse events
Time Frame: 7 days
|
7 days
|
Safety, by blood pressure measurement
Time Frame: 7 days
|
7 days
|
Anorectal muscle contractility, by anorectal manometry
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gilberto De Nucci, PhD, Galeno Desenvolvimento de Pesquisas
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Diseases
- Rectal Diseases
- Anus Diseases
- Fissure in Ano
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Natriuretic Agents
- Diuretics, Osmotic
- Diuretics
- Nitric Oxide Donors
- Isosorbide
- Isosorbide Dinitrate
- Isosorbide-5-mononitrate
Other Study ID Numbers
- GDN 001/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Fissure
-
State Scientific Centre of Coloproctology, Russian...Recruiting
-
Istanbul Medipol University HospitalCompletedAnal Fissure ChronicTurkey
-
Treviso Regional HospitalCompletedAnal Fissure | Anal Fissure ChronicItaly
-
Mansoura UniversityCompleted
-
Zagazig UniversityCompletedChronic Anal FissureEgypt
-
University of NinevehCompleted
-
Mansoura UniversityCompleted
-
Hospital General Universitario ElcheCompletedChronic Anal FissureSpain
-
Hvidovre University HospitalUnknownFocus: Anal Incontinence After Lateral Sphincterotomy for Chronic Anal FissureDenmark
-
KTO Karatay UniversityIstanbul Medipol University HospitalCompletedPRP | Anal Fissure ChronicTurkey
Clinical Trials on Isosorbide Mononitrate
-
Danish Headache CenterCompleted
-
Cairo UniversityCompletedIUD Insertion PainEgypt
-
BayerMerck Sharp & Dohme LLCCompletedCoronary Artery DiseaseGermany
-
Biolab Sanus FarmaceuticaWithdrawnHealthy Subjects | Pharmacokinetics
-
Cairo UniversityUnknown
-
Al-Azhar UniversityNot yet recruiting
-
Aljazeera HospitalSuez Canal UniversityUnknown
-
The University of Texas Health Science Center,...National Kidney FoundationTerminatedHypertension | Proteinuria | Kidney InjuryUnited States
-
Adrian HernandezMayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); University of...CompletedHeart FailureUnited States
-
Danish Headache CenterCompletedHealthy | HeadacheDenmark